The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 04, 2017
Filed:
Nov. 08, 2011
Bert Vogelstein, Baltimore, MD (US);
Kenneth Kinzler, Baltimore, MD (US);
Nickolas Papadopoulos, Towson, MD (US);
Donald Williams Parsons, Ellicott City, MD (US);
Rebecca J. Leary, Baltimore, MD (US);
Meng LI, Baltimore, MD (US);
Xiaosong Zhang, Baltimore, MD (US);
Sian Jones, Baltimore, MD (US);
Gregory J. Riggins, Baltimore, MD (US);
Victor Velculescu, Dayton, MD (US);
Darell Bigner, Mebane, NC (US);
Hai Yan, Chapel Hill, NC (US);
Bert Vogelstein, Baltimore, MD (US);
Kenneth Kinzler, Baltimore, MD (US);
Nickolas Papadopoulos, Towson, MD (US);
Donald Williams Parsons, Ellicott City, MD (US);
Rebecca J. Leary, Baltimore, MD (US);
Meng Li, Baltimore, MD (US);
Xiaosong Zhang, Baltimore, MD (US);
Sian Jones, Baltimore, MD (US);
Gregory J. Riggins, Baltimore, MD (US);
Victor Velculescu, Dayton, MD (US);
Darell Bigner, Mebane, NC (US);
Hai Yan, Chapel Hill, NC (US);
The Johns Hopkins University, Baltimore, MD (US);
Duke University, Durham, NC (US);
Abstract
Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis.